Last updated on November 2017

A phase 3 randomized double-blind placebo-controlled, parallel-group multicenter, fixed dose clinical trial evaluating efficacy, safety and tolerability of investigational medication in patients with Bipolar 1 depression.


Brief description of study

A phase 3 randomized double-blind placebo-controlled, parallel-group multicenter, fixed dose clinical trial evaluating efficacy, safety and tolerability of investigational medication in patients with Bipolar 1 depression.

Detailed Study Description

The purpose of this study is to investigate safety and efficacy of investigational medication in the treatment of bipolar 1 depression.

Clinical Study Identifier: TX11607

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Svitlana Shylman

SPRI Clinical Trials Brooklyn
Brooklyn, NY USA
  Connect »